DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Spinal Muscular Atrophy | Niche & Rare Disease Landscape and Forecast | US/EU5 | 2018
Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive muscle weakness due to the loss of anterior horn motor neurons. Nearly all cases of SMA are caused by…
Systemic Lupus Erythematosus | Current Treatment: Physician Insights | Systemic Lupus Erythematosus (Excluding Active Lupus Nephritis and Severe CNS Manifestations) | US | 2018
MARKET OUTLOOK SLE is an autoimmune disease characterized by varied symptoms ranging from general fatigue to serious organ manifestations. Options available to treat SLE are limited, with…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 2 | 2018
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-…
Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Adult | US | 2018
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…